Omniose, a company developing polysaccharide conjugate vaccines against serious bacterial threats, is developing a Klebsiella pneumoniae vaccine. Klebsiella pneumoniae is a leading cause of life-threatening sepsis in newborns, as well as healthcare-associated infections, including pneumonia, bloodstream infections, wound or surgical site infections, and meningitis. Klebsiella pneumoniae has developed a high rate of antibiotic resistance to many classes of antimicrobials and was attributed to or associated with an estimated 600,000 deaths globally in 2019.
Omniose is developing multivalent bioconjugate vaccines targeting both the capsular and O-antigen polysaccharides of Klebsiella pneumoniae.
The research and development of the vaccines are done in Omniose's St. Louis lab space at BioGenerator Labs at BioSTL.



Subscribe now ➤ https://bit.ly/2NNQiyM

For more great content from HEC Media check us out at:
Facebook ➤ http://bit.ly/1WPZEek
Twitter ➤ http://bit.ly/22qZDNU
Instagram ➤ http://bit.ly/1THSOnM